Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 209 participants.

Also called NCT02081118

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 209 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02081118
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02081118. Randomized; triple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Intervention (Drug)
HM11260C
Intervention (Drug)
Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct02081118
Content hash
ccc2ffc51f62d1d4d52f502228053c780816ba4c76bcc4d853ae503df2adf4c8